Alkermes plc (NASDAQ:ALKS) Q3 2023 Earnings Call Transcript

Craig Hopkinson: Yeah. Obviously, as we move forward and plan our Phase 2 program, we’ll be meeting with the agency to discuss those plans. And I believe that those discussions will inform the length of both our Phase 2 as well as our Phase 3 program as we move forward.

Charles Duncan: Last question, regarding visual disturbances in the human volunteers, and I know it’s a very small sample, but I guess I’m wondering if you would speculate on there being a pharmacological target or is that just really a sporadic observation, how normal humans could be different than NT1 patients if there is a target or some reason to wonder about that?

Craig Hopkinson: Interesting, we’ve only seen the visual disturbances in healthy volunteers. Once again, we’ve only seen the four out of a denominator of 80 healthy volunteers. These were sort of mild adverse events that are transient, largely just were vigilant and increased light sensitivity. In terms of mechanism, I think at this point in time, it’s obviously something that we’re evaluating and monitoring for and we haven’t seen any visual disturbances in patients today.

Operator: Thank you. At this time, I’d like to turn the floor back over to Ms. Coombs for closing comments.

Sandra Coombs: Thanks, Donna. Thanks, everyone, for joining us on the call today. A copy of the prepared remarks is now posted on our website in case any portions were inaudible and you’d like to reference that, it’s on the events section of the website. And please don’t hesitate to reach out to us at the company if we can be helpful. Thank you very much.

Operator: Ladies and gentlemen, thank you for your participation. This concludes today’s event. You may disconnect your lines or log off the webcast and enjoy the rest of your day.